{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:29:28Z","timestamp":1791548968266,"version":"4.3.4"},"reference-count":105,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtha.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:51:56Z","timestamp":1716475916000},"page":"2129-2139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Thrombotic risk associated with gender-affirming hormone therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Tanya L. Kowalczyk","family":"Mullins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-9068","authenticated-orcid":false,"given":"Eric S.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.05.015_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jadohealth.2017.04.014","article-title":"Risk and protective factors in the lives of transgender\/gender nonconforming adolescents","volume":"61","author":"Eisenberg","year":"2017","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.jtha.2024.05.015_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamasurg.2017.6231","article-title":"Temporal trends in gender-affirming surgery among transgender patients in the United States","volume":"153","author":"Canner","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jtha.2024.05.015_bib3","series-title":"The Report of the 2015 U.S. Transgender Survey","author":"James","year":"2016"},{"key":"10.1016\/j.jtha.2024.05.015_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0978","article-title":"Mental health outcomes in transgender and nonbinary youths receiving gender-affirming care","volume":"5","author":"Tordoff","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.05.015_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.717766","article-title":"Short-term effects of gender-affirming hormone therapy on dysphoria and quality of life in transgender individuals: a prospective controlled study","volume":"12","author":"Foster Skewis","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jtha.2024.05.015_bib6","article-title":"Hormone therapy, mental health, and quality of life among transgender people: a systematic review","volume":"5","author":"Baker","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.jtha.2024.05.015_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJMoa2206297","article-title":"Psychosocial functioning in transgender youth after 2 years of hormones","volume":"388","author":"Chen","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jadohealth.2023.12.024","article-title":"Changes in gender dysphoria, interpersonal minority stress, and mental health among transgender youth after one year of hormone therapy","volume":"74","author":"Chelliah","year":"2024","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.jtha.2024.05.015_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s10508-018-1278-4","article-title":"A\u00a0Cross-sectional multicenter study of multidimensional body image in adolescents and adults with gender dysphoria before and after transition-related medical interventions","volume":"47","author":"Becker","year":"2018","journal-title":"Arch Sex Behav"},{"key":"10.1016\/j.jtha.2024.05.015_bib10","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.14626","article-title":"Transgender patients and the role of the coagulation clinician","volume":"17","author":"Connors","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib11","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"key":"10.1016\/j.jtha.2024.05.015_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V63.3.657.657","article-title":"Estrogen stimulates von Willebrand factor production by cultured endothelial cells","volume":"63","author":"Harrison","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.015_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.thromres.2003.11.014","article-title":"Estrogen administration enhances thrombin generation in rats","volume":"112","author":"Ohashi","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.015_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/AOG.0b013e3181626d1b","article-title":"Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial","volume":"111","author":"Johnson","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.05.015_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jth.12560","article-title":"Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers","volume":"12","author":"Blondon","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ajh.24064","article-title":"Hypercoagulability in adolescent girls on oral contraceptives-global coagulation profile and estrogen receptor polymorphisms","volume":"90","author":"Zia","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.05.015_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0037-1613958","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","article-title":"Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives","volume":"60","author":"Harris","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.05.015_bib20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1615717","article-title":"The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial","volume":"85","author":"Hoibraaten","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.CIR.100.7.717","article-title":"Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Study","volume":"100","author":"Cushman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.015_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.16666","article-title":"The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk","volume":"191","author":"Khialani","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.015_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/rth2.12058","article-title":"Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S","volume":"2","author":"Ellery","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A\u00a0randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0049-3848(98)90006-8","article-title":"The effects of oestrogen administration on the plasma free protein S and C4b-binding protein","volume":"49","author":"Melissari","year":"1988","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.015_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.015_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/ATVBAHA.120.315033","article-title":"Sex-specific platelet activation through protease-activated Receptors reverses in myocardial infarction","volume":"41","author":"Soo","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.05.015_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0049-3848(85)90220-8","article-title":"Effects of estradiol on platelet aggregation in mouse mesenteric arterioles and ex\u00a0vivo","volume":"39","author":"Rosenblum","year":"1985","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.015_bib29","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.STR.16.6.980","article-title":"Effects of estradiol on platelet aggregation in cerebral microvessels of mice","volume":"16","author":"Rosenblum","year":"1985","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.05.015_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00404-011-2098-0","article-title":"Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women","volume":"285","author":"Rank","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jtha.2024.05.015_bib31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"Meade","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.05.015_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","author":"Oral","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.jtha.2024.05.015_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jth.12054","article-title":"Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women","volume":"11","author":"Stegeman","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/13697137.2019.1703939","article-title":"Association of oral estradiol dose\/levels with coagulation measures in early\/late postmenopausal women","volume":"23","author":"Sriprasert","year":"2020","journal-title":"Climacteric"},{"key":"10.1016\/j.jtha.2024.05.015_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejogrb.2017.08.023","article-title":"Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women","volume":"217","author":"Pirog","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2024.05.015_bib36","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib37","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-023549","article-title":"Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy","volume":"147","author":"Mullins","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2024.05.015_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0010-7824(79)90036-2","article-title":"Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women","volume":"19","author":"Humpel","year":"1979","journal-title":"Contraception"},{"key":"10.1016\/j.jtha.2024.05.015_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/09513590.2012.730567","article-title":"Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration","volume":"29","author":"Polac","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jtha.2024.05.015_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2008.07.004","article-title":"Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis","volume":"78","author":"Jensen","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.jtha.2024.05.015_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.015_bib42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/jth.15256","article-title":"Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen","volume":"19","author":"Scheres","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib43","first-page":"27","article-title":"Dynamic impact of hormone therapy on laboratory values in transgender patients over time","volume":"6","author":"Allen","year":"2021","journal-title":"J\u00a0Appl Lab Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman","year":"2014","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jtha.2024.05.015_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4158\/EP15950.OR","article-title":"Metabolic effects of hormone therapy in transgender patients","volume":"22","author":"Fernandez","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jtha.2024.05.015_bib46","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1210\/jc.2007-0746","article-title":"Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals","volume":"92","author":"Mueller","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jadohealth.2017.08.005","article-title":"Physiologic response to gender-affirming hormones among transgender youth","volume":"62","author":"Olson-Kennedy","year":"2018","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.jtha.2024.05.015_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/andr.12382","article-title":"Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review","volume":"5","author":"Velho","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.jtha.2024.05.015_bib49","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/andr.12485","article-title":"Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence","volume":"6","author":"Defreyne","year":"2018","journal-title":"Andrology"},{"key":"10.1016\/j.jtha.2024.05.015_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211051546","article-title":"Effects of testosterone treatment on transgender males: a single-institution study","volume":"9","author":"Korpaisarn","year":"2021","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","article-title":"Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years","volume":"106","author":"Madsen","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2009.008417","article-title":"Hematocrit and risk of venous thromboembolism in a general population. The Tromso study","volume":"95","author":"Braekkan","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.015_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","article-title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","volume":"11","author":"Nguyen","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2024.05.015_bib54","first-page":"3002","article-title":"Effects of three different testosterone formulations in female-to-male transsexual persons","volume":"11","author":"Pelusi","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib55","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1210\/jc.2003-030520","article-title":"Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people","volume":"88","author":"Toorians","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib56","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/bloodadvances.2022008061","article-title":"Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy","volume":"7","author":"Roy","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.015_bib57","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1182\/bloodadvances.2023010027","article-title":"Crucial roles of red blood cells and platelets in whole blood thrombin generation","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.015_bib58","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2012-05-427856","article-title":"Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation","volume":"120","author":"Whelihan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.015_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/lgbt.2019.0260","article-title":"Lower serum estradiol levels in assigned female at birth transgender people with initiation of testosterone therapy: results from the European Network for the Investigation of Gender Incongruence","volume":"7","author":"Defreyne","year":"2020","journal-title":"LGBT Health"},{"key":"10.1016\/j.jtha.2024.05.015_bib60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1076029615619486","article-title":"Thrombophilia in 67 patients with thrombotic events after starting testosterone therapy","volume":"22","author":"Glueck","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib61","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/j.amjmed.2020.12.018","article-title":"Testosterone replacement therapy causing extensive portal and mesenteric vein thrombosis","volume":"134","author":"Poirier-Blanchette","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103596","article-title":"Masculinizing hormone therapy effect on breast tissue: changes in estrogen and androgen receptors in transgender female-to-male mastectomies","volume":"72","author":"Chaum","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.jtha.2024.05.015_bib63","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V85.6.1504.bloodjournal8561504","article-title":"High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)","volume":"85","author":"Rosendaal","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.015_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1160\/TH04-11-0759","article-title":"Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study","volume":"94","author":"Wu","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib65","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.05.015_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(97)00204-7","article-title":"Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on oral contraceptives and the health of young women","volume":"57","author":"Heinemann","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.jtha.2024.05.015_bib67","first-page":"1347","article-title":"Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels","volume":"89","author":"Legnani","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.015_bib68","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.05.015_bib69","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.015_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.160.1.49","article-title":"Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects","volume":"160","author":"Bloemenkamp","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib71","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2024.05.015_bib72","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.015_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jth.12060","article-title":"The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy","volume":"11","author":"Roach","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.015_bib75","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.015_bib76","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","article-title":"Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial","volume":"289","author":"Wassertheil-Smoller","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.05.015_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2519","article-title":"Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study","volume":"340","author":"Renoux","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.015_bib78","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/gme.0b013e3182175e5c","article-title":"Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy","volume":"18","author":"Laliberte","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.jtha.2024.05.015_bib79","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.05.015_bib80","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/01.AOG.0000428645.90795.d9","article-title":"556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.05.015_bib81","first-page":"169205","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib82","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.015_bib83","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/ejendo\/lvad170","article-title":"Cardiovascular disease in transgender people: a systematic review and meta-analysis","volume":"190","author":"van Zijverden","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jtha.2024.05.015_bib84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-13-0493","article-title":"Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study","volume":"169","author":"Wierckx","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jtha.2024.05.015_bib85","first-page":"1065","article-title":"Association between use of exogenous testosterone therapy and risk of venous thrombotic events among exogenous testosterone treated and untreated men with hypogonadism","volume":"195","author":"Li","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jtha.2024.05.015_bib86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chest.2016.05.007","article-title":"Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: a retrospective cohort study of the Veterans Administration Database","volume":"150","author":"Sharma","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.05.015_bib87","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.015_bib88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism","volume":"180","author":"Walker","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib89","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis","volume":"95","author":"Fernandez-Balsells","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2024.05.015_bib90","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2018.10.023","article-title":"Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis","volume":"172","author":"Houghton","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.015_bib91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jtha.2024.05.015_bib92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/MBC.0000000000000126","article-title":"Testosterone, thrombophilia, thrombosis","volume":"25","author":"Glueck","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.05.015_bib93","first-page":"11","article-title":"Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events","volume":"8","author":"Glueck","year":"2018","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.05.015_bib94","article-title":"Superior sagittal venous sinus thrombosis in a patient with illicit testosterone use","volume":"11","author":"Hashmi","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2024.05.015_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206023","article-title":"Mesenteric vein thrombosis caused by secondary polycythaemia from AndroGel","volume":"2014","author":"Katz","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2024.05.015_bib96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/hematolrep15020029","article-title":"Testosterone usage leading to pulmonary embolisms and deep vein thrombosis: a case report and review of the literature","volume":"15","author":"Menakuru","year":"2023","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2024.05.015_bib97","article-title":"An interesting presentation of testosterone-induced arterial thrombosis","volume":"13","author":"Thompson","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2024.05.015_bib98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13256-021-02805-6","article-title":"Portomesenteric venous thrombosis in a postmenopausal female with testosterone implant: a case report","volume":"15","author":"Campitruz","year":"2021","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.jtha.2024.05.015_bib99","series-title":"Testosterone cypionate injection prescribing information","year":"2022"},{"key":"10.1016\/j.jtha.2024.05.015_bib100","series-title":"AndroGel\u00ae (testosterone gel) 1.62% for topical use prescribing information","year":"2016"},{"key":"10.1016\/j.jtha.2024.05.015_bib101","series-title":"Testosterone undecanoate injection for intramuscular use prescribing information","year":"2020"},{"key":"10.1016\/j.jtha.2024.05.015_bib102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jtha.2024.05.015_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ICB.0000000000000924","article-title":"Unusual cause of branch retinal artery occlusion: polycythemia in a transgender man from unregulated testosterone use","volume":"16","author":"Choy","year":"2022","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.jtha.2024.05.015_bib104","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1097\/MPH.0000000000001755","article-title":"Venous thromboembolism in a transgender adolescent on testosterone therapy: a case report and literature review","volume":"42","author":"Fan","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.05.015_bib105","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1097\/MPH.0000000000002442","article-title":"Affirming hormone treatment for a transgender adolescent after a venous thromboembolic event","volume":"44","author":"Penney","year":"2022","journal-title":"J\u00a0Pediatr Hematol Oncol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T01:12:22Z","timestamp":1754010742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624002988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1538783624002988"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.015","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic risk associated with gender-affirming hormone therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}